Document is current
Any future updates will be listed below
-
Authors
Oda, Naohiro
Hotta, Kastuyuki
Ninomiya, Kiichiro
Minami, Daisuke
Ichihara, Eiki
Murakami, Toshi
Yokoyama, Toshihide
Ichikawa, Hirohisa
Chikamori, Kenichi
Takigawa, Nagio
Ochi, Nobuaki
Harita, Shingo
Maeda, Yoshinobu
Kiura, Katsuyuki
- License Information
-
More Information
Article History
Received: 30 June 2018
Accepted: 24 September 2018
First Online: 1 October 2018
Compliance with ethical standards
:
: NO has received grants from Boehringer-Ingelheim, during the conduct of the study. KH has received grants and personal fees from Boehringer-Ingelheim, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from Ono Pharmaceutical, personal fees from Nihon Kayaku, personal fees from Taiho Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, personal fees from Astellas, grants and personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Eli Lilly Japan, grants and personal fees from Merck Sharp Dohme, outside the submitted work. KN has received grants from Boehringer-Ingelheim, during the conduct of the study; personal fees from Bristol-Myers Squibb, other from AstraZeneca, personal fees from Ono Pharmaceutical, outside the submitted work. EI has received grants from Boehringer-Ingelheim, during the conduct of the study; personal fees from AstraZeneca, personal fees from Ono Pharmaceutical, grants and personal fees from Merck Sharp Dohme, personal fees from Chugai Pharmaceutical, personal fees from Novartis, personal fees from Bristol-Myers Squibb, grants from Eli Lilly Japan, outside the submitted work. TY has received personal fees from AstraZeneca, personal fees from Ono Pharmaceutical, personal fees from Taiho Pharmaceutical, personal fees from Eli Lilly Japan, outside the submitted work. KC has received grants and personal fees from Chugai pharmaceutical, grants from Bristol-Myers Squibb, personal fees from Eli Lilly Japan, grants from Taiho Pharmaceutical, personal fees from Ono Pharmaceutical, outside the submitted work;. NT has received grants and personal fees from Eli Lilly Japan, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi-Sankyo Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Pfizer Inc. Japan, grants and personal fees from Boehringer-Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Kyowa Hakko Kirin, grants from Nippon Kayaku, grants from Takeda Pharmaceutical, personal fees from Merck Sharp Dohme, personal fees from Novartis, outside the submitted work. YM has received grants from Bristol-Myers Squibb, Pfizer, Otsuka Pharmaceutical, Kyowa Hakko Kirin, Merck Sharp Dohme, Eisai, Mochida Pharmaceutical, Ono Pharmaceutical, Astellas, Meiji Seika Pharma, Asahi Kasei Pharma., Nippon Shinyaku, Toyama Chemical., and Yakult Honsha, outside the submitted work. KK has received from personal fees from Nippon Boehringer-Ingelheim, during the conduct of the study; grants from Chugai Pharmaceutical, grants from Pfizer, grants from Novartis, grants and personal fees from Taiho pharmaceutical, grants from Eli Lilly Japan, grants and personal fees from Ono Pharmaceutical, personal fees from AstraZeneca, personal fees from Nippon Kayaku, personal fees from Daiichi Sankyo, personal fees from Shionogi, outside the submitted work. All other authors declare that they have no conflict of interest.
